ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1324

Golimumab, A Human Anti-TNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks As Monotherapy in Patients with Active Rheumatoid Arthritis Despite Disease Modifying Antirheumatic Drug Therapy: Week 104 Results of Clinical, Radiographic and Safety Assessments

Tsutomu Takeuchi1, Masayoshi Harigai2, Yoshiya Tanaka3, Hisashi Yamanaka4, Naoki Ishiguro5, Kazuhiko Yamamoto6, Minoru Kanazawa7, Yoshinori Murakami8, Toru Yoshinari9, Daniel Baker10, Nobuyuki Miyasaka11 and Takao Koike12, 1Keio University School of Medicine, Tokyo, Japan, 2Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, 3The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 4Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 5Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, 6Department of Allergy & Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 7Director of Respiratory Center Professor of Respiratory, Medicine Saitama Medical University, Moroyama, Iruma-Gun, Saimata, Japan, 8Medical writing, Janssen Pharmaceutical KK, Tokyo, Japan, 92-6-18, Kitahama, Chuo-ku, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, 10Janssen Research & Development, LLC., Spring House, PA, 11Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, 12Sapporo medical center NTT EC, Sapporo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Japanese and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Golimumab, A Human Anti-TNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks as Monotherapy in Patients with Active Rheumatoid Arthritis Despite Disease Modifying Antirheumatic Drug Therapy: Week 104 Results of Clinical, Radiographic and Safety Assessments

Background/Purpose: To assess the long-term efficacy and safety of golimumab (GLM) as monotherapy in Japanese patients (pts) with active rheumatoid arthritis (RA) despite DMARD therapy. 

Methods: GO-MONO is a multicenter, randomized, double-blind, placebo (PBO)-controlled study in pts with active RA despite treatment with DMARDs. Pts were randomized to SC PBO, GLM50 mg, or GLM100 mg q4wks as monotherapy. At wk16, pts in the PBO group (grp) crossed over (CO) GLM50 mg q4wks. Treatment with GLM continued to wk120. Primary endpoint was the proportion of pts achieving ACR20 at wk14. Secondary endpoints included ACR50, ACR70, and ACR-N, DAS28 and HAQ and changes from BL to wks 24/52/104/120 in total modified vdH-Sharp (vdH-S) score. Data were analyzed using all patients receiving ≥1 dose of study treatment. Missing clinical response data were not imputed. For vdH-S score, treatment grp comparisons at wks 52/104 were based on initial randomized grps. Missing data were imputed using median change from BL in total vdH-S scores (TSS) of all pts or by linear extrapolation. Wk52 data have been reported; wk104 results of efficacy are now reported. Safety data from all treatment period are reported as incidence per 100-patient-years.

Results: Long-term efficacy and safety data are shown in the Table. Clinical remission was defined as DAS28(ESR) < 2.6 and HAQ remission was defined as HAQ < 0.5 maintained between wk52 and wk104. Median changes from baseline to wk52 were 1.0 in PBO and GLM 50mg, and 0 in GLM100 mg. Median changes from baseline to wk104 in PBO, GLM 50 and 100 mg were 1.5, 1.25 and 1.0, respectively. The proportions of pts with changes in TSS greater than the smallest detectable change (SDC) were also maintained from wk52 and wk104. Proportion of pts with no progression (change in TSS≤0) were slightly decrease from wk52 to wk104 in both of GLM 50 mg and 100 mg. Safety finding are also summarized in the Table. Two deaths were reported, one in GLM 50 mg (brain stem haemorrhage) and one in 100 mg (pancreatic carcinoma). Incidences of SAEs and AEs leading to discontinuation in GLM 50 mg were higher than 100 mg. There were no cases of tuberculosis or lymphoma reported.

Conclusion: Treatment with GLM50 mg and 100 mg monotherapy sustained the efficacy of signs/symptoms during 104wks. Inhibition of structural damage in GLM 100 mg was relatively greater than GLM 50mg, however the progression went on slowly during 104wks in both of the GLM groups. The GLM safety profile was similar to other anti-TNF agents.

 

 

Evaluation at

PBO a)

GLM

50 mg

100 mg

Efficacy results

DAS(ESR) remission (<2.6)

n/N(%)

Wk 52

Wk 104

17/85 ( 20.0)

27/78 ( 34.6)

18/84 ( 21.4)

29/74 ( 39.2)

26/94 ( 27.7)

32/90 ( 35.6)

HAQ remission (<0.5)

n/N(%)

Wk 52

Wk 104

46/85 ( 54.1)

51/78 ( 65.4)

37/84 ( 44.0)

46/74 ( 62.2)

52/94 ( 55.3)

53/90 ( 58.9)

Change from BL in TSS b)

n

Mean (SD)

Median

Wk 52

Wk 104

83

2.81 (7.139)

1.0

83

3.61 (8.922)

1.5

82

3.31 (6.192)

1.0

82

4.34 (7.720)

1.25

93

1.56 (5.093)

0.0

93

2.64 (6.507)

1.0

Pts with progression based on TSS >SDC c)

n/N(%)

Wk 52

Wk 104

17/83 ( 20.5)

16/75 ( 21.3)

16/82 ( 19.5)

16/72 ( 22.2)

16/92 ( 17.4)

21/89 ( 23.6)

Pts with change ≤0 in TSS from baseline

n/N(%)

Wk 52

Wk 104

37/105 ( 35.2)

28/75 ( 37.3)

46/101 ( 45.5)

22/72 ( 30.6)

54/102 ( 52.9)

40/89 ( 44.9)

Safety results from all treatment period

 

Avg duration of follow-up (wks)

15.0

97.1

110.9

Incidence per 100 patient-years (95%CI)

Deaths,

SAEs

Patients with AEs leading to discontinuation

Patients with 1 or more serious infections

0.00 (0.00, 9.88)

6.63 (0.80, 23.94)

9.95 (2.05, 29.09)

3.30 (0.08, 18.38)

0.28 (0.01, 1.55)

14.47 (10.74, 19.08)

7.83 (5.20, 11.32)

3.09 (1.54, 5.53)

0.46 (0.01, 2.56)

7.92 (4.61, 12.68)

5.07 (2.53, 9.07)

3.75 (1.62, 7.39)

a) All patients received placebo crossed over to GLM50 mg afer wk 16.

b) Missing data were imputed using median change from BL of all pts or by linear extrapolation.

c) SDC = 5.18 at wk 52, SDC = 5.65 at wk 104

 

 


Disclosure:

T. Takeuchi,

Janssen Research and Development, LLC,

;

M. Harigai,

Janssen Research and Development, LLC,

;

Y. Tanaka,

Janssen Research and Development, LLC,

;

H. Yamanaka,

Janssen Research and Development, LLC,

;

N. Ishiguro,

Janssen Research and Development, LLC,

;

K. Yamamoto,

Janssen Research and Development, LLC,

;

M. Kanazawa,

Janssen Research and Development, LLC,

;

Y. Murakami,

Janssen Pharmaceutical K.K,

3;

T. Yoshinari,

Janssen Research and Development, LLC,

;

D. Baker,

Janssen Research and Development, LLC,

3;

N. Miyasaka,

Janssen Research and Development, LLC,

;

T. Koike,

Janssen Research and Development, LLC,

.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/golimumab-a-human-anti-tnf-monoclonal-antibody-administered-subcutaneously-every-four-weeks-as-monotherapy-in-patients-with-active-rheumatoid-arthritis-despite-disease-modifying-antirheumatic-drug-t/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology